As political leaders from around the world get ready to meet at the COP 28 climate conference, life science companies are taking steps to encourage sustainabili 29 November 2023
Liver specialist Terns Pharmaceuticals has announced top-line data from the Phase IIa DUET trial at the American Association for the Study of Liver Diseases (AA 13 November 2023
The American business of Israeli drugmaker Teva Pharmaceutical has announced new Huntington’s disease (HD) data to be presented at the ongoing Huntington Study 3 November 2023
AstraZeneca has presented positive results from the real-world ZORA trial, at the annual congress of the American Society of Nephrology (ASN). 3 November 2023
At the annual meeting of the American College of Gastroenterology (ACG), Johnson & Johnson has presented data from the Phase III QUASAR trial. 25 October 2023
Germany’s BioNTech has presented positive Phase I/II on its CAR-T cell therapy candidate BNT211 in advanced solid tumors at the European Society of Medical Onco 24 October 2023
At the 2023 annual congress of the European Society of Medical Oncology (ESMO), Johnson & Johnson has presented important new data for Rybrevant (amivantamab-vm 24 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.